focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDDDD.L Share News (DDDD)

  • There is currently no data for DDDD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: RWS and James Cropper sink on profit warnings

Wed, 23rd Mar 2022 11:21

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

----------

AIM - WINNERS

----------

4D Pharma PLC, up 37% at 61.45 pence, 12-month range 24.46p-135.00p. The pharmaceutical company says its therapeutic treatment MRx0518, in combination Merck's Keytruda, met its primary efficacy endpoint ahead of trial enrolment completion.

----------

AIM - LOSERS

----------

RWS Holdings PLC, down 27% at 342.00p, 12-month range 326.00p-701.00p. The technology-enabled language services provider warns its annual performance is set to be at the lower end of expectations.

RWS will no longer provide services or technology to Russian-owned businesses, and also expects reduced demand for translation into Russian from non-Russian owned companies. As a result, revenue growth from the Language Services unit is set to moderate, and RWS's overall performance for the year is anticipated to be at the lower end of market expectations.

----------

James Cropper PLC, down 18% at 1,002.00p, 12-month range 1,002.00p-1,650.00p. Shares in the paper products manufacturer hit a 12-month low as it warns it will miss previous expectations for profit. For the year ending March 26, James Cropper notes 30% growth in sales, ahead of prior market expectations due to strong demand across all divisions. However, it now expects adjusted pretax profit of GBP3.5 million, a sharp rise from GBP1.1 million the year before, but below prior expectations of GBP4.9 million. This is due to the conflict between Russia and Ukraine, and the resulting jump in energy costs, which affected the Paper division the most, due to being the most energy-intensive division.

----------

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
24 May 2021 09:42

More positive data reported from 4D Pharma trial of 'Blautix'

(Sharecast News) - Biotherapeutic pharmaceutical company 4D Pharma announced additional positive data from its completed phase 2 trial of 'LBP Blautix' on Monday, in subjects with irritable bowel syndrome with constipation (IBS-C) or with diarrhea (IBS-D).

Read more
24 May 2021 09:20

4d Pharma posts more "positive" results from Blautix probe

4d Pharma posts more "positive" results from Blautix probe

Read more
17 May 2021 16:05

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
19 Apr 2021 10:50

4D Pharma forms partnership with Parkinson's UK to improve treatments

4D Pharma forms partnership with Parkinson's UK to improve treatments

Read more
16 Apr 2021 15:17

DIRECTOR DEALINGS: Tesco chair invests GBP100,000; Dechra exec sells

DIRECTOR DEALINGS: Tesco chair invests GBP100,000; Dechra exec sells

Read more
1 Apr 2021 12:00

TRADING UPDATES: 4D Pharma loss widens on rise in administrative costs

TRADING UPDATES: 4D Pharma loss widens on rise in administrative costs

Read more
22 Mar 2021 09:25

4D Pharma completes reversal into Nasdaq listing via US Spac

4D Pharma completes reversal into Nasdaq listing via US Spac

Read more
17 Mar 2021 18:40

TRADING UPDATES: Ceres Power eyes move to Main Market by mid-2022

TRADING UPDATES: Ceres Power eyes move to Main Market by mid-2022

Read more
11 Mar 2021 16:11

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
1 Mar 2021 16:41

EXECUTIVE CHANGES: New CFOs for Sensyne, Focusrite, Bango, 4D Pharma

EXECUTIVE CHANGES: New CFOs for Sensyne, Focusrite, Bango, 4D Pharma

Read more
1 Mar 2021 14:33

4D Pharma taps John Beck as its new finance chief

(Sharecast News) - Biotherapeutic pharmaceutical company 4D Pharma announced the appointment of John Beck as its chief financial officer and member of its management team on Monday.

Read more
1 Mar 2021 14:33

4D Pharma taps John Beck as its new finance chief

(Sharecast News) - Biotherapeutic pharmaceutical company 4D Pharma announced the appointment of John Beck as its chief financial officer and member of its management team on Monday.

Read more
1 Mar 2021 10:14

IN BRIEF: 4D Pharma appoints former Ritter finance chief as own CFO

IN BRIEF: 4D Pharma appoints former Ritter finance chief as own CFO

Read more
26 Feb 2021 10:26

4D Pharma Registration Statements Effective; Longevity Buy Progresses

4D Pharma Registration Statements Effective; Longevity Buy Progresses

Read more
8 Feb 2021 16:25

4D Pharma inks collaboration with Merck and Pfizer

(Sharecast News) - Biotherapeutics developer 4D Pharma announced a clinical trial collaboration and supply agreement with Merck and Pfizer on Monday, for 'Bavencio', or avelumab).

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.